{"id":"recombinant-von-willebrand-factor","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL4298126","moleculeType":"Unknown"},"_dailymed":{"setId":"53b6d198-6175-4a26-8606-dc0d2a0f12d6","title":"VONVENDI (VON WILLEBRAND FACTOR (RECOMBINANT)) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Von Willebrand factor (vWF) is a critical blood glycoprotein that mediates platelet adhesion to damaged blood vessel walls and serves as a carrier protein for coagulation factor VIII. The recombinant form is produced through genetic engineering and functions identically to endogenous vWF, restoring hemostatic function in patients with von Willebrand disease or factor VIII deficiency by enabling proper platelet plug formation and stabilizing factor VIII levels.","oneSentence":"Recombinant von Willebrand factor replaces or supplements the natural von Willebrand factor protein to restore platelet adhesion and coagulation factor VIII binding.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:40.267Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Von Willebrand disease (Type 1, 2, and 3)"},{"name":"Factor VIII deficiency associated with von Willebrand disease"}]},"trialDetails":[{"nctId":"NCT06883240","phase":"","title":"An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-29","conditions":"Von Willebrand Disease, Type 3","enrollment":40},{"nctId":"NCT06433778","phase":"","title":"A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-12-16","conditions":"Von Willebrand Disease (VWD)","enrollment":34},{"nctId":"NCT07404644","phase":"","title":"An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-02-19","conditions":"Von Willebrand Disease (vWD)","enrollment":13},{"nctId":"NCT06579144","phase":"PHASE1","title":"Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-02-24","conditions":"Hemophilia A","enrollment":24},{"nctId":"NCT06118372","phase":"PHASE1","title":"Recombinant vWF Concentrate and ECMO","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-10-03","conditions":"Bleeding Disorder","enrollment":12},{"nctId":"NCT06716814","phase":"PHASE3","title":"Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-03-06","conditions":"Severe Haemophilia A","enrollment":104},{"nctId":"NCT07129343","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-10-13","conditions":"Von Willebrand Disease (VWD)","enrollment":20},{"nctId":"NCT03695978","phase":"","title":"Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients","status":"RECRUITING","sponsor":"Octapharma","startDate":"2018-02-13","conditions":"Haemophilia A","enrollment":200},{"nctId":"NCT04344860","phase":"PHASE3","title":"Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial","status":"COMPLETED","sponsor":"Nicoletta C Machin","startDate":"2021-06-04","conditions":"Von Willebrand Diseases, Postpartum Hemorrhage","enrollment":20},{"nctId":"NCT05582993","phase":"PHASE3","title":"A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-06","conditions":"Von Willebrand Disease (VWD)","enrollment":24},{"nctId":"NCT05817812","phase":"PHASE3","title":"A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2023-07-31","conditions":"Hemophilia A, Severe","enrollment":93},{"nctId":"NCT04161495","phase":"PHASE3","title":"A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2019-11-19","conditions":"Factor VIII Deficiency","enrollment":159},{"nctId":"NCT04759131","phase":"PHASE3","title":"Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2021-02-19","conditions":"Hemophilia A","enrollment":74},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT06173024","phase":"","title":"Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)","status":"AVAILABLE","sponsor":"Takeda","startDate":"","conditions":"Von Willebrand Disease (VWD)","enrollment":""},{"nctId":"NCT03879135","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2019-04-01","conditions":"Von Willebrand Disease (VWD)","enrollment":38},{"nctId":"NCT04644575","phase":"PHASE3","title":"Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bioverativ, a Sanofi company","startDate":"2021-02-23","conditions":"Hemophilia A","enrollment":261},{"nctId":"NCT02932618","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)","status":"RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2017-11-06","conditions":"Von Willebrand Disease","enrollment":31},{"nctId":"NCT04887324","phase":"","title":"Real-life Data of Constitutional Von Willebrand Disease in Western France","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2023-07-07","conditions":"Von Willebrand Diseases","enrollment":922},{"nctId":"NCT02460458","phase":"","title":"Type 3 Von Willebrand International Registries Inhibitor Prospective Study","status":"COMPLETED","sponsor":"Fondazione Angelo Bianchi Bonomi","startDate":"2012-11-05","conditions":"Type 3 Von Willebrand's Disease","enrollment":265},{"nctId":"NCT03344003","phase":"","title":"Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq","status":"TERMINATED","sponsor":"Octapharma","startDate":"2018-06-28","conditions":"Hemophilia A","enrollment":14},{"nctId":"NCT02606045","phase":"PHASE3","title":"Minimize Menorrhagia in Women With Von Willebrand Disease","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2019-02-07","conditions":"Von Willebrand Diseases","enrollment":39},{"nctId":"NCT05265078","phase":"","title":"A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-06-08","conditions":"Von Willebrand Disease (VWD)","enrollment":102},{"nctId":"NCT03205163","phase":"PHASE1, PHASE2","title":"A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2017-08-28","conditions":"Hemophilia A","enrollment":16},{"nctId":"NCT02973087","phase":"PHASE3","title":"rVWF IN PROPHYLAXIS","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-11-16","conditions":"Von Willebrand Disease","enrollment":29},{"nctId":"NCT02283268","phase":"PHASE3","title":"Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-04-01","conditions":"Von Willebrand Disease","enrollment":24},{"nctId":"NCT01410227","phase":"PHASE3","title":"Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-11-01","conditions":"Von Willebrand Disease","enrollment":49},{"nctId":"NCT00816660","phase":"PHASE1","title":"Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2008-12-01","conditions":"Von Willebrand Disease","enrollment":32},{"nctId":"NCT01051544","phase":"NA","title":"Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2009-09-25","conditions":"Severe Hemophilia A","enrollment":""},{"nctId":"NCT00524225","phase":"PHASE2","title":"IL-11 in Adults With Von Willebrand Disease Undergoing Surgery","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2008-02","conditions":"Von Willebrand Disease","enrollment":3},{"nctId":"NCT00524342","phase":"PHASE2","title":"IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia","status":"COMPLETED","sponsor":"Margaret Ragni","startDate":"2008-01","conditions":"Von Willebrand Disease","enrollment":7},{"nctId":"NCT01064284","phase":"PHASE4","title":"Survey of Inhibitors in Plasma-Product Exposed Toddlers","status":"COMPLETED","sponsor":"Fondazione Angelo Bianchi Bonomi","startDate":"2010-01","conditions":"Hemophilia A","enrollment":303}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":126,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rVWF, Vonvendi","vonicog alfa","Vonvendi"],"phase":"marketed","status":"active","brandName":"Recombinant Von Willebrand factor","genericName":"Recombinant Von Willebrand factor","companyName":"Nicoletta C Machin","companyId":"nicoletta-c-machin","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant von Willebrand factor replaces or supplements the natural von Willebrand factor protein to restore platelet adhesion and coagulation factor VIII binding. Used for Von Willebrand disease (Type 1, 2, and 3), Factor VIII deficiency associated with von Willebrand disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}